Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients

Jennifer R. King; Edward P. Acosta; Ram Yogev; Andrew Wiznia; Joyce Kraimer; Bobbie Graham; Vincent Carey; Paula Britto; Patrick Jean-Philippe; John Moye; Douglas Watson

doi:10.1097/INF.0b013e3181861d8b

Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients

Jennifer R. King, Edward P. Acosta, Ram Yogev, Andrew Wiznia, Joyce Kraimer, Bobbie Graham, Vincent Carey, Paula Britto, Patrick Jean-Philippe, John Moye, Douglas Watson

Pediatrics

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m twice daily and efavirenz (EFV) 350 mg/m once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient.

Original language	English (US)
Pages (from-to)	159-161
Number of pages	3
Journal	Pediatric Infectious Disease Journal
Volume	28
Issue number	2
DOIs	https://doi.org/10.1097/INF.0b013e3181861d8b
State	Published - Feb 2009

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Pediatrics, Perinatology, and Child Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/INF.0b013e3181861d8b

Cite this

King, J. R., Acosta, E. P., Yogev, R., Wiznia, A., Kraimer, J., Graham, B., Carey, V., Britto, P., Jean-Philippe, P., Moye, J., & Watson, D. (2009). Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. Pediatric Infectious Disease Journal, 28(2), 159-161. https://doi.org/10.1097/INF.0b013e3181861d8b

@article{eebaa6dbb7e742ae8b56c00182311480,

title = "Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients",

abstract = "The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m twice daily and efavirenz (EFV) 350 mg/m once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient.",

author = "King, {Jennifer R.} and Acosta, {Edward P.} and Ram Yogev and Andrew Wiznia and Joyce Kraimer and Bobbie Graham and Vincent Carey and Paula Britto and Patrick Jean-Philippe and John Moye and Douglas Watson",

year = "2009",

month = feb,

doi = "10.1097/INF.0b013e3181861d8b",

language = "English (US)",

volume = "28",

pages = "159--161",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

King, JR, Acosta, EP, Yogev, R, Wiznia, A, Kraimer, J, Graham, B, Carey, V, Britto, P, Jean-Philippe, P, Moye, J & Watson, D 2009, 'Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients', Pediatric Infectious Disease Journal, vol. 28, no. 2, pp. 159-161. https://doi.org/10.1097/INF.0b013e3181861d8b

TY - JOUR

T1 - Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients

AU - King, Jennifer R.

AU - Acosta, Edward P.

AU - Yogev, Ram

AU - Wiznia, Andrew

AU - Kraimer, Joyce

AU - Graham, Bobbie

AU - Carey, Vincent

AU - Britto, Paula

AU - Jean-Philippe, Patrick

AU - Moye, John

AU - Watson, Douglas

PY - 2009/2

Y1 - 2009/2

N2 - The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m twice daily and efavirenz (EFV) 350 mg/m once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient.

AB - The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m twice daily and efavirenz (EFV) 350 mg/m once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient.

UR - http://www.scopus.com/inward/record.url?scp=61949484973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61949484973&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e3181861d8b

DO - 10.1097/INF.0b013e3181861d8b

M3 - Article

C2 - 19106779

AN - SCOPUS:61949484973

SN - 0891-3668

VL - 28

SP - 159

EP - 161

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 2

ER -

Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this